295 related articles for article (PubMed ID: 34325001)
1. G6PD inhibits ferroptosis in hepatocellular carcinoma by targeting cytochrome P450 oxidoreductase.
Cao F; Luo A; Yang C
Cell Signal; 2021 Nov; 87():110098. PubMed ID: 34325001
[TBL] [Abstract][Full Text] [Related]
2. Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition.
Lu M; Lu L; Dong Q; Yu G; Chen J; Qin L; Wang L; Zhu W; Jia H
Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):370-380. PubMed ID: 29471502
[TBL] [Abstract][Full Text] [Related]
3. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
4. LncRNA SNHG1 upregulates FANCD2 and G6PD to suppress ferroptosis by sponging miR-199a-5p/3p in hepatocellular carcinoma.
Zhou L; Zhang Q; Cheng J; Shen X; Li J; Chen M; Zhou C; Zhou J
Drug Discov Ther; 2023 Sep; 17(4):248-256. PubMed ID: 37599085
[TBL] [Abstract][Full Text] [Related]
5. Construction of a competing endogenous RNA network to analyse glucose-6-phosphate dehydrogenase dysregulation in hepatocellular carcinoma.
Wang P; Yang X; Liu D; Yang Y; Zhang Y; Wang G
Biosci Rep; 2022 Jun; 42(6):. PubMed ID: 35712981
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the circular RNA/microRNA/glucose-6-phosphate dehydrogenase axis in the pathological mechanism of hepatocellular carcinoma.
Wang Y; Zhou XY; Lu XY; Chen KD; Yao HP
Hepatobiliary Pancreat Dis Int; 2021 Dec; 20(6):530-534. PubMed ID: 34548225
[TBL] [Abstract][Full Text] [Related]
7. miR-206-G6PD axis regulates lipogenesis and cell growth in hepatocellular carcinoma cell.
Wang A; Chen B; Jian S; Cai W; Xiao M; Du G
Anticancer Drugs; 2021 Jun; 32(5):508-516. PubMed ID: 33735119
[TBL] [Abstract][Full Text] [Related]
8. Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways.
Li M; He X; Guo W; Yu H; Zhang S; Wang N; Liu G; Sa R; Shen X; Jiang Y; Tang Y; Zhuo Y; Yin C; Tu Q; Li N; Nie X; Li Y; Hu Z; Zhu H; Ding J; Li Z; Liu T; Zhang F; Zhou H; Li S; Yue J; Yan Z; Cheng S; Tao Y; Yin H
Nat Cancer; 2020 Jul; 1(7):735-747. PubMed ID: 35122041
[TBL] [Abstract][Full Text] [Related]
9. Changes in glucose-6-phosphate dehydrogenase expression results in altered behavior of HBV-associated liver cancer cells.
Hu H; Ding X; Yang Y; Zhang H; Li H; Tong S; An X; Zhong Q; Liu X; Ma L; Liu Q; Liu B; Lu Z; Zhang D; Hu P; Ren H
Am J Physiol Gastrointest Liver Physiol; 2014 Sep; 307(6):G611-22. PubMed ID: 24994855
[TBL] [Abstract][Full Text] [Related]
10. TSP50 promotes hepatocyte proliferation and tumour formation by activating glucose-6-phosphate dehydrogenase (G6PD).
Zhang X; Gao F; Ai H; Wang S; Song Z; Zheng L; Wang G; Sun Y; Bao Y
Cell Prolif; 2021 Apr; 54(4):e13015. PubMed ID: 33630390
[TBL] [Abstract][Full Text] [Related]
11. WTAP-mediated m6A modification on circCMTM3 inhibits hepatocellular carcinoma ferroptosis by recruiting IGF2BP1 to increase PARK7 stability.
Chen S; Xia H; Sheng L
Dig Liver Dis; 2023 Jul; 55(7):967-981. PubMed ID: 36586770
[TBL] [Abstract][Full Text] [Related]
12. PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis.
Hong X; Song R; Song H; Zheng T; Wang J; Liang Y; Qi S; Lu Z; Song X; Jiang H; Liu L; Zhang Z
Gut; 2014 Oct; 63(10):1635-47. PubMed ID: 24352616
[TBL] [Abstract][Full Text] [Related]
13. BAG3 elevation inhibits cell proliferation via direct interaction with G6PD in hepatocellular carcinomas.
Kong DH; Li S; Du ZX; Liu C; Liu BQ; Li C; Zong ZH; Wang HQ
Oncotarget; 2016 Jan; 7(1):700-11. PubMed ID: 26621836
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of four ferroptosis-related gene signatures and their correlations with immune implication in hepatocellular carcinoma.
Zhang Y; Ren H; Zhang C; Li H; Guo Q; Xu H; Cui L
Front Immunol; 2022; 13():1028054. PubMed ID: 36304446
[TBL] [Abstract][Full Text] [Related]
15. CircIL4R facilitates the tumorigenesis and inhibits ferroptosis in hepatocellular carcinoma by regulating the miR-541-3p/GPX4 axis.
Xu Q; Zhou L; Yang G; Meng F; Wan Y; Wang L; Zhang L
Cell Biol Int; 2020 Nov; 44(11):2344-2356. PubMed ID: 32808701
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis.
Kowalik MA; Guzzo G; Morandi A; Perra A; Menegon S; Masgras I; Trevisan E; Angioni MM; Fornari F; Quagliata L; Ledda-Columbano GM; Gramantieri L; Terracciano L; Giordano S; Chiarugi P; Rasola A; Columbano A
Oncotarget; 2016 May; 7(22):32375-93. PubMed ID: 27070090
[TBL] [Abstract][Full Text] [Related]
17. Glucose-6-phosphate dehydrogenase promotes the proliferation and migration of lung adenocarcinoma cells via the STAT3 signaling pathway.
Wu W; Yu F; Yu N; Zhu Y; Wu W; Gao P; Chen C
J Mol Histol; 2022 Apr; 53(2):215-225. PubMed ID: 35028787
[TBL] [Abstract][Full Text] [Related]
18. G6PD facilitates clear cell renal cell carcinoma invasion by enhancing MMP2 expression through ROS‑MAPK axis pathway.
Zhang Q; Han Q; Yang Z; Ni Y; Agbana YL; Bai H; Yi Z; Yi X; Kuang Y; Zhu Y
Int J Oncol; 2020 Jul; 57(1):197-212. PubMed ID: 32319593
[TBL] [Abstract][Full Text] [Related]
19. Identification of ferroptosis-related genes for overall survival prediction in hepatocellular carcinoma.
Luo L; Yao X; Xiang J; Huang F; Luo H
Sci Rep; 2022 Jun; 12(1):10007. PubMed ID: 35705729
[TBL] [Abstract][Full Text] [Related]
20. Inverse Association between Glucose‒6‒Phosphate Dehydrogenase Deficiency and Hepatocellular Carcinoma.
Dore MP; Vidili G; Marras G; Assy S; Pes GM
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1069-1073. PubMed ID: 29699064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
